Clinical Trials Browser

Phase 1/2 × NIH × ibritumomab tiuxetan × Clear all

NCT00012298 2018-08-09

Radiolabeled Monoclonal Antibody Plus Rituximab With and Without Filgrastim and Interleukin-11 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Phase 1/2 Terminated

81 enrolled 16 charts

LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone

NCT00064246 2013-01-25

Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative Disorder

Phase 1/2 Completed

Burkitt Lymphoma, Waldenstrom Macroglobulinemia, Lymphoma, Large B-Cell, Diffuse